Therefore, we believe that similarly to FSTL1, CER1 may also inhibit the activation of the BMP2 pathway, which would induce undifferentiation of glioma cells and cause poor prognosis in patients with glioma. This evidence concerns the gene FSTL1 and central nervous system cancer.